Search

Your search keyword '"Vandongen, Ja"' showing total 31 results
Start Over "Vandongen, Ja"
31 results on '"Vandongen, Ja"'

1. EFFECTS OF RADIOTHERAPY AND SURGERY IN EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS

Author

Abe, O., Abe, R., Asaishi, K., Enomoto, K., Hattori, T., Iino, Y., Kikuchi, K., Koyama, H., Sawa, K., Uchino, J., Yoshida, M., Vandevelde, Ao, Vermorken, Jb, Foroglou, P., Giokas, G., Lissaios, B., Harvey, Vj, Holdaway, Tm, Kay, Rg, Mason, Bh, Forbes, Jf, Focan, C., Lobelle, Jp, Peek, U., Oates, Gd, Powell, J., Bastert, G., Rauschecker, H., Sauer, R., Sauerbrei, W., Schauer, A., Schumacher, M., Gelman, Rs, Henderson, Ic, Shapiro, Cl, Hancock, Ak, Jackson, S., Ragaz, J., Delozier, T., Macelesech, J., Haybittle, Jl, Cirrincione, C., Korzun, A., Weiss, Rb, Wood, Wc, Baum, M., Houghton, J., Riley, D., Dent, Dm, Gudgeon, Ca, Hacking, A., Horgan, K., Hughes, L., Stewart, Hj, Gordon, Nh, Davis, Hl, Owen, Jr, Meier, P., Howell, A., Ribeiro, Gc, Swindell, R., Albano, J., Deoliveira, Cf, Gervasio, H., Gordilho, J., Carstensen, B., Palshof, T., Johansen, H., Korzeniowski, S., Skolyszewski, J., Andersen, Kw, Axelsson, Ck, Blicherttoft, M., Mouridsen, Ht, Overgaard, M., Rose, C., Corcoran, N., Trampisch, Hj, Abeloff, Md, Carbone, Pc, Glick, J., Gray, R., Tormey, Dc, Bartelink, H., Fentiman, Is, Paridaens, R., Vandriel, Ojr, Sylvester, Rj, Vandevelde, Cjh, Vanderschueren, E., Vandongen, Ja, Welvaart, K., Scanlon, Ef, Schurman, S., Deschryver, A., Yosef, Hma, Mcardle, Cs, Smith, Dc, Lara, Pc, Boccardo, F., Izuo, M., Morishita, Y., Bentley, A., Doran, Z., Hayward, Jl, Rubens, Rd, Kaufmann, M., Jonat, W., Scheurlen, H., Vonfournier, D., Klefstrom, P., Cuzick, J., Margreiter, R., Cavalli, F., Collins, J., Gelber, Rd, Goldhirsch, A., ISLEY, MR, Lindtner, J., Price, Kn, Rudenstam, Cm, Bliss, Jm, Chilvers, Ced, Coombes, Rc, Marty, M., Brufman, G., Hayat, H., Borovik, R., Robinson, E., Pannuti, F., Takashima, S., Yasutomi, T., Sonoo, H., Yamashita, J., Ogawa, M., Nomura, Y., Bonte, J., Tengrup, I., Tennvallnittby, L., Martin, P., Romain, S., Ahmann, D., Schaid, Dj, Buzdar, Au, Smith, T., Hakes, T., Norton, L., Wittes, R., Delahuerta, R., Sainz, Mg, Bonadonna, G., Delvecchio, M., Valagussa, P., Veronesi, U., Dubois, Jb, Bianco, Ar, Lippman, Me, Pierce, Lj, Simon, R., Steinberg, Sm, Brown, A., Fisher, B., Redmond, C., Wolmark, N., Jackson, Im, Palmer, Mk, Ingle, Jn, Bengtsson, No, Larsson, Lg, Lythgoe, Jp, Kissin, M., Hannisdal, E., Varhaug, Je, Blamey, Rw, Mitchell, Ak, Robertson, Jfr, Nakamura, Y., Mathe, G., Misset, Jl, Clarke, Ea, Mclaughlin, Jr, Clark, Rm, Levine, M., Morimoto, K., Gundersen, S., Hauerjensen, M., Host, H., Crossley, E., Durrant, K., Harris, A., Beighton, A., Chadbon, D., Clarke, M., Collins, R., Davies, C., Evans, V., Godwin, J., Greaves, E., Harwood, C., James, S., Mead, G., Muldahl, A., Peto, R., Tooth, A., Wheatley, K., Rambert, P., Asselain, B., Salmon, Rj, Vilcoq, Jr, Arriagada, R., Hill, C., Laplanche, A., Le, Mg, Spielmann, M., Cocconi, G., Diblasio, B., Catalano, R., Creech, Rh, Brockschmidt, J., COOPER, MR, Andrysek, O., Barkmanova, J., Treurnietdonker, Ad, Vanputten, Wlj, Easton, D., Powles, Tj, Gazet, Jc, Semiglazov, V., Deshpande, N., Dimartino, L., Douglas, P., Lindtner, A., Notter, G., Nissenmeyer, R., Forrest, Apm, Jack, W., Mcdonald, C., Moller, Tr, Ryden, S., Carstensen, J., Hatschek, T., Soderberg, M., Carpenter, Jt, Albain, K., Crowley, J., Green, S., Osborne, Ck, Rutquist, Le, Wallgren, A., Holm, Le, Castiglione, M., Fluckiger, H., Thurlimann, B., Hermann Brenner, Hercbergs, A., Yoshimoto, M., Deboer, G., Paterson, Ahg, Pritchard, Ki, Meakin, Jw, Panzarella, T., Naja, A., Bahi, J., Reid, M., Spittler, M., Senanayake, F., Holmberg, L., Sevelda, P., Zielinsky, Cc, Jakesz, R., Buchanan, Rb, Cross, M., Dunn, Ja, Gillespie, Wm, Kelly, K., Morrison, Jm, Litton, A., Chlebowski, Rt, Bezwoda, Wr, and Caffier, H.

2. Ovarian ablation in early breast cancer: Overview of the randomised trials

Author

Clarke, M., Collins, R., Davies, C., Godwin, J., Gray, R., Peto, R., Abe, O., Abe, R., Enomoto, K., Kikuchi, K., Koyama, H., Nomura, Y., Sakai, K., Sugimachi, K., Tominaga, T., Uchino, J., Yoshida, M., Vandevelde, Ao, Vandongen, Ja, Vermorken, Jb, Arvelakis, A., Giokas, G., Lissaios, B., Harvey, Vj, Holdaway, Tm, Kay, Rg, Mason, Bh, Coates, A., Forbes, Jf, Focan, C., Lobelle, Jp, Peek, U., Oates, Gd, Powell, J., Bastert, G., Rauschecker, H., Sauer, R., Sauerbrei, W., Schauer, A., Schumacher, M., Durand, M., Mauriac, L., Bartholomeus, S., Piccart, Mj, Gelman, Rs, Henderson, Ic, Shapiro, Cl, Hancock, Ak, Masood, Mb, Parker, D., Price, Jj, Jackson, S., Ragaz, J., Delozier, T., Macelesech, J., Haybittle, Jl, Cirrincione, C., Korzun, A., Weiss, Rb, Wood, Wc, Baum, M., Houghton, J., Riley, D., Dent, Dm, Gudgeon, Ca, Hacking, A., Horgan, K., Hughes, L., Stewart, Hj, Gordon, Nh, Davis, Hl, Lehingue, Y., Owen, Jr, Meier, P., Howell, A., Ribeiro, Gc, Swindell, R., Albano, J., Deoliveira, Cf, Gervasio, H., Gordilho, J., Carstensen, B., Palshof, T., Johansen, H., Korzeniowski, S., Skolyszewski, J., Andersen, Kw, Axelsson, Ck, Blicherttoft, M., Mouridsen, Ht, Overgaard, M., Rose, C., Corcoran, N., Trampisch, Hj, Abeloff, Md, Carbone, Pc, Glick, J., Tormey, Dc, Rossbach, J., Scanlon, Ef, Schurman, S., Deschryver, A., Yosef, Hma, Mcardle, Cs, Smith, Dc, Lara, Pc, Boccardo, F., Erazo, A., Medina, Jy, Izuo, M., Morishita, Y., Bentley, A., Doran, Z., Fentiman, Is, Hayward, Jl, Rubens, Rd, Kaufmann, M., Jonat, W., Scheurlen, H., Vonfournier, D., Fountzilas, G., Klefstrom, P., Blomqvist, C., Cuzick, J., Margreiter, R., Castiglione, M., Cavalli, F., Collins, J., Forbes, J., Gelber, Rd, Goldhirsch, A., Lindtner, J., Price, Kn, Rudenstam, Cm, Senn, Hj, Bliss, Jm, Chilvers, Ced, Coombes, Rc, Marty, M., Borovik, R., Brufman, G., Hayat, H., Robinson, E., Wigler, N., Pannuti, F., Takashima, S., Tasutomi, T., Sonoo, H., Yamashita, J., Ogawa, M., Hupperets, Psgj, Bonte, J., Tengrup, I., Tennvallnittby, L., Martin, P., Romain, S., Ahmann, D., Schaid, Dj, Buzdar, Au, Smith, T., Hakes, T., Norton, L., Wittes, R., Delahuerta, R., Sainz, Mg, Bonadonna, G., Delvecchio, M., Valagussa, P., Veronesi, U., Dubois, Jb, Bianco, Ar, Lippman, Me, Pierce, Lj, Simon, R., Steinberg, Sm, Brown, A., Fisher, B., Redmond, C., Wolmark, N., Jackson, Im, Palmer, Mk, Ingle, Jn, Suman, Vj, Bengtsson, No, Larsson, Lg, Lythgoe, Jp, Kissin, M., Hannisdal, E., Varhaug, Je, Nissenmeyer, R., Blamey, Rw, Mitchell, Ak, Robertson, Jfr, Nakamura, Y., Mathe, G., Misset, Jl, Abuzahra, Ht, Clarke, Ea, Mclaughlin, Jr, Clark, Rm, Levine, M., Myles, Jd, Pater, Jl, Pritchard, Ki, Morimoto, K., Sawa, K., Takatsuka, Y., Gundersen, S., Hauerjensen, M., Host, A., Crossley, E., Durrant, K., Harris, A., Beighton, A., Evans, V., Greaves, E., Harwood, C., James, S., Lau, E., Mead, G., Muldal, A., Naughton, A., Tooth, A., Wheatley, K., Rambert, P., Asselain, B., Salmon, Rj, Vilcoq, Jr, Rodrigo Arriagada, Hill, C., Laplanche, A., Le, Mg, Speilmann, M., Cocconi, G., Diblasio, B., Catalano, R., Creech, Rh, Brockschmidt, J., Cooper, MR, Andrysek, O., Barkmanova, J., Falkson, Cj, Abraham, M., Klijn, Jgm, Treurnietdonker, Ad, Vanputten, Wlj, Easton, D., Powles, Tj, Gazet, Jc, Semiglazov, V., Deshpande, N., Dimartino, L., Douglas, P., Host, H., Bryant, Ajs, Ewing, Gh, Krushenkosloski, Jl, Forrest, Apm, Jack, W., Mcdonald, C., Moller, Tr, Ryden, S., Carstensen, J., Hatschek, T., Soderberg, M., Carpenter, Jt, Albain, K., Crowley, J., Green, S., Martino, S., Osborne, Ck, Ravdin, Pm, Rutqvist, Le, Wallgren, A., Holm, Le, Yoshimoto, M., Deboer, G., Paterson, Ahg, Meakin, Jw, Panzarella, T., Naja, A., Bahi, J., Reid, M., Spittle, M., Senanayake, F., Bergh, J., Holmberg, L., Sevelda, P., Zielinsky, Cc, Jakesz, R., Gnant, M., Buchanan, Rb, Cross, M., Dunn, Ja, Gillespie, Wm, Kelly, K., Morrison, Jm, Litton, A., Chlebowski, Rt, Bezwoda, Wr, Caffier, H., Clarke, M, Collins, R, Davies, C, Godwin, J, Gray, R, Peto, R, Abe, O, Abe, R, Enomoto, K, Kikuchi, K, Koyama, H, Nomura, Y, Sakai, K, Sugimachi, K, Tominaga, T, Uchino, J, Yoshida, M, vandeVelde, A, vanDongen, J, Vermorken, J, Arvelakis, A, Giokas, G, Lissaios, B, Harvey, V, and Holdaway, T

Subjects
Oncology, medicine.medical_specialty, Breast cancer, business.industry, Internal medicine, medicine, Ovarian Ablation, General Medicine, business, medicine.disease, Early breast cancer
Abstract

Background Among women with early breast cancer, the effects of ovarian ablation on recurrence and death have been assessed by several randomised trials that now have long follow-up. In this report, the Early Breast Cancer Trialists' Collaborative Group present their third 5-yearly systematic overview (meta-analysis), now with 15 years' follow-up. Methods In 1995, information was sought on each patient in any randomised trial of ovarian ablation or suppression versus control that began before 1990. Data were obtained for 12 of the 13 studies that assessed ovarian ablation by irradiation or surgery, all of which began before 1980, but not for the four studies that assessed ovarian suppression by drugs, all of which began after 1985. Menopausal status was not consistently defined across trials; therefore, the main analyses are limited to women aged under 50 (rather than “premenopausal”) when randomised. Oestrogen receptors were measured only in the trials of ablation plus cytotoxic chemotherapy versus the same chemotherapy alone. Findings Among 2102 women aged under 50 when randomised, most of whom would have been premenopausal at diagnosis, 1130 deaths and an additional 153 recurrences were reported. 15-year survival was highly significantly improved among those allocated ovarian ablation (52·4 vs46·1%, 6·3 [SD 2·3] fewer deaths per 100 women, logrank 2p=0·001), as was recurrence-free survival (45·0 vs 39·0%, 2p=0·0007). The numbers of events were too small for any subgroup analyses to be reliable. The benefit was, however, significant both for those with (“node positive”) and for those without (“node negative”) axillary spread when diagnosed. In the trials of ablation plus cytotoxic chemotherapy versus the same chemotherapy alone, the benefit appeared smaller (even for women with oestrogen receptors detected on the primary tumour) than in the trials of ablation in the absence of chemotherapy (where the observed survival improvements were about six per 100 node-negative women and 12 per 100 node-positive women). Among 1354 women aged 50 or over when randomised, most of whom would have been perimenopausal or postmenopausal, there was only a nonsignificant improvement in survival and recurrence-free survival. improves long-term survival, at least in the absence of chemotherapy. Further randomised evidence is needed on the additional effects of ovarian ablation in the presence of other adjuvant treatments, and to assess the relevance of hormone-receptor measurements. Interpretation In women aged under 50 with early breast cancer, ablation of functioning ovaries significantly.

3. A Study of Volumetric Variation in the Excision Cavity during Hypofractionated Whole Breast Radiotherapy.

Author

Youssief Mohammed, Ayatallah Ali and Ahmed, Shimaa

Subjects
CONFIDENCE intervals, MULTIVARIATE analysis, SIMULATION methods in education, REGRESSION analysis, TREATMENT effectiveness, DESCRIPTIVE statistics, RADIATION doses, COMPUTED tomography, LUMPECTOMY, RADIOTHERAPY, BREAST tumors, LONGITUDINAL method
Abstract

Background: Based on the special pattern of recurrence in the excision cavity, secondary computed tomography (CT) can be introduced after hypofractionated whole breast radiotherapy with early breast cancer, aiming for accurate delineation of tumor bed boost and reduced toxicity. This study aimed to assess the volumetric changes in the lumpectomy cavity before and after hypofractionated whole breast radiation therapy (WBRT) and related clinical factors. Method: This prospective study was designed and CT simulation was done for 45 patients from September 2019 to April 2020, two radiotherapy treatment planning were generated for each patient before and after hypofractionated WBRT. The tumor bed is defined using surgical clips, seroma, and postoperative alterations. Based on the original CT and tumor bed boost CT, statistically significant decrease was examined. The relationship between various factors and the volume decrease in the excision cavity was examined. Results: The median value of reduction in the excision cavity was 15.4 cm³with the statistical significance (P < 0.001). In multivariate linear regression, the significant variable, which predict the volume reduction, was the presence of seroma (B = 24.48, confidence interval, 13.09 to 35.87, P < 0.001). Conclusion: our results suggested significant benefit from resimulation before boost planning especially for patients with clinical evident seroma. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

6. Oncoplastic breast reconstruction: Principles, current techniques, and future directions.

Author

Salibian AA, Olson B, Shauly O, and Patel KM

Subjects
Breast, Esthetics, Female, Humans, Mastectomy, Segmental methods, Breast Neoplasms surgery, Mammaplasty methods, Surgeons
Abstract

Oncoplastic breast reconstruction has improved esthetic results after breast-conserving surgery with low complication rates and stable oncologic outcomes. Basic principles can be applied across different volume displacement and replacement techniques including restoration of breast shape and symmetry through esthetic incisions while eliminating dead space. Technique selection is guided by several factors including breast size, resection-to-breast ratio, and patient desires. A surgeon familiar with all techniques will allow individualization of treatment and optimization of outcomes., (© 2022 Wiley Periodicals LLC.)

Published
2022
Full Text
View/download PDF

7. N-cap helix nucleation: methods and their applications.

Author

Wang, Dongyuan, Qin, Xuan, Zhao, Hui, and Li, Zigang

Abstract

Recapitulation of well-defined α-helices could result in constrained peptide mimetics with preferable secondary structures and enhanced therapeutic properties for various purposes. Among the helix-stabilizing strategies, the nucleation strategies are able to maximize recognition specificity of the original sequence without compromising the molecular recognition surface. In this review, current methodologies of helix nucleation are introduced including their constructing strategies, structure features and proof of concept biological applications. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

8. TUmor-volume to breast-volume RAtio for improving COSmetic results in breast cancer patients (TURACOS); a randomized controlled trial.

Author

Lagendijk, M., Vos, E. L., Koning, A. H. J., Hunink, M. G. M., Pignol, J. P., Corten, E. M. L., de Monye, C., van Deurzen, C. H. M., van Dam, J. H., Vrijland, W. W., Contant, C. M. E., Verhoef, C., van Lankeren, W., and Koppert, L. B.

Subjects
BREAST surgery, BREAST cancer, QUALITY of life, CANCER patients, TUMORS, ANTHROPOMETRY, BREAST, MAMMOGRAMS, BREAST tumors, COMPARATIVE studies, DECISION making, MATHEMATICAL models, RESEARCH methodology, MEDICAL cooperation, QUESTIONNAIRES, RESEARCH, STATISTICAL sampling, ULTRASONIC imaging, THEORY, LUMPECTOMY, EVALUATION research, RANDOMIZED controlled trials
Abstract

Background: Cosmetic result following breast conserving surgery (BCS) for cancer influences quality of life and psychosocial functioning in breast cancer patients. A preoperative prediction of expected cosmetic result following BCS is not (yet) standard clinical practice and therefore the choice for either mastectomy or BCS is still subjective. Recently, we showed that tumour volume to breast volume ratio as well as tumour location in the breast are independent predictors of superior cosmetic result following BCS. Implementation of a prediction model including both factors, has not been studied in a prospective manner. This study aims to improve cosmetic outcome by implementation of a prediction model in the treatment decision making for breast cancer patients opting for BCS.Methods/design: Multicentre, single-blinded, randomized controlled trial comparing standard preoperative work-up to a preoperative work-up with addition of the prediction model. Tumour volume to breast volume ratio and tumour location in the breast will be used to predict cosmetic outcome in invasive breast cancer patients opting for BCS. Three dimensional (3D)-ultrasonography will be used to measure the tumour volume to breast volume ratio needed for the prediction model. Sample size was estimated based on a 14% improvement in incidence of superior cosmetic result one year after BCS (71% in the control group versus 85% in the intervention group). Primarily cosmetic outcome will be evaluated by a 6-member independent panel. Secondary endpoints include; (1) patient reported outcome measured by BREAST-Q, EORTC-QLQ-C30/BR23 and EQ-5D-5 L (2) cosmetic outcome as assessed through the BCCT.core software, (3) radiation-induced reaction (4) surgical treatment performed, (5) pathological result and (6) cost-effectiveness. Follow-up data will be collected for 3 years after surgery or finishing radiotherapy.Discussion: This randomized controlled trial examines the value of a preoperative prediction model for the treatment-decision making. It aims for a superior cosmetic result in breast cancer patients opting for BCS. We expect improvement of patients' quality of life and psychosocial functioning in a cost-effective way.Trial Registration: Prospectively registered, February 17th 2015, at 'Nederlands Trialregister - NTR4997 '. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

9. Overview on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant radiotherapy for breast cancer.

Author

Meattini, Icro, Guenzi, Marina, Fozza, Alessandra, Vidali, Cristiana, Rovea, Paolo, Meacci, Fiammetta, and Livi, Lorenzo

Abstract

Conservative management of breast cancer represents the standard treatment for early disease. Breast conserving surgery associated with radiotherapy for stage I-II has been proven to be as equally effective as mastectomy in term of local control, distant disease, and overall survival. The growing minimal invasive surgical approach on the axillary region, and the new breast reconstructive techniques, will probably lead to a significant decrease of the rate of side-effects related to mastectomy. Therefore, the adverse events caused by adjuvant radiation still remain a challenge. Cutaneous, pulmonary and cardiac toxicity represent the main toxicities of adjuvant radiotherapy for breast cancer. Safety profile of radiation is strongly dependent on the multidisciplinary management of the single case (systemic treatment, endocrine therapy, surgery), individual characteristics (i.e., co-morbidities, age, habits), and radiation-related aspects. Radiation techniques development, and facilities implementation concerning organs-at-risk sparing systems (i.e., image-guided radiotherapy, tracking systems, respiratory gating), represent brand new tools for the clinical oncologist, that would certainly minimize toxicity profile in the next future. However, data reported from published literature will greatly help physicians, to give to the patients appropriate counseling regarding the efficacy and potential adverse events of treatments, thus optimizing the informed decision-making process. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

10. An Attempt to Independently Verify the Utility of the Van Nuys Prognostic Index for Ductal Carcinoma In Situ.

Author

MacAusland, Stephanie G., Hepel, Jaroslaw T., Chong, Frank K., Galper, Shira L., Gass, Jennifer S., Ruthazer, Robin, and Wazer, David E.

Subjects
CANCER, BREAST tumors, PATIENTS, SURGICAL excision, OPERATIVE surgery
Abstract

The article presents a study which attempted to independently verify the utility of the Van Nuys Prognostic Index (VNPI) for ductal carcinoma in situ (DCIS). It cites the use of the VNPI in predicting the risk of ipsilateral breast tumor recurrence (IBTR) after excision of DCIS. It suggests that VNPI or margin width alone is not a valid tool with which to assist in the stratification of patients after excision alone for their risk of IBTR at 5 years.

Published
2007
Full Text
View/download PDF

16. Cytologic evaluation of lumpectomy margins in patients with ductal carcinoma in situ: Clinical outcome.

Author

Cox, Charles, Hyacinthe, Micheline, Gonzalez, Ricardo, Lyman, Gary, Reintgen, Douglas, Ku, Ni, Miller, Marcia, Greenberg, Harvey, and Nicosia, Santo

Abstract

Backround: Breast conservation therapy is controversial for ductal carcinoma in situ (DCIS) due to recently reported high recurrence rates. We believe that cytologic evaluation of lumpectomy margins improves efficiency and leads to a lower recurrence rate following lumpectomy for DCIS. Methods: A prospectively accrued database of 1255 breast cancer patients at the H. Lee Moffitt Cancer Center and Research Institute was found to have 218 patients with DCIS (17.4%). Of those 218 cases, 114 were treated with lumpectomy, axillary dissection, and radiation therapy; the remaining 104 patients were treated with mastectomy with or without reconstruction. Imprint cytology was used to evaluate all lumpectomy margins. Permanent sections and imprint cytology were reviewed by the same pathologist. Results: All lumpectomy specimens (116 tumors in 114 patients) were evaluated. The median follow up was 57.5 months (range 2–110 months). One hundred and three patients with 104 tumors were selected on the basis of pure DCIS (with or without microinvasion), and treated with lumpectomy, axillary dissection and radiation therapy. Of the 104 tumors utilizing attempted breast conservation therapy, 7 (6.6%) required mastectomy. There were 6 recurrences (6.1%) with a median time for recurrence of 47.5 months (range 27–85 months); four recurrences were comedo and two were noncomedo at original diagnosis. Conclusions: The determination of lumpectomy margins in DCIS patients using imprint cytology leads to an overall recurrence rate of 6.1% with reduction in operative time, and re-excision rate. Significant recurrence rates were associated with microinvasion and multifocal tumors (28%) versus simple DCIS at 5 years. Breast conservation therapy and surgical margin determination with imprint cytology for DCIS is a cost-effective and reliable method of treatment for simple DCIS. [ABSTRACT FROM AUTHOR]

Published
1997
Full Text
View/download PDF

28. Breast Cancer

Author

S. Eva Singletary and S. Eva Singletary

Subjects
Breast--Cancer--Treatment, Breast Neoplasms--therapy
Abstract

Breast Cancer, the second volume in the MD Anderson Solid Tumor Oncology series, this book provides the general surgeon, surgical oncologist, and medical oncologist with the state-of-the art multimodality care for breast cancer. Divided into five sections, the text brings the field's recognized esperts addressing the current status of breast imaging, breast pathology, the role of breast surgery including management of in situ and early stage carcinoma, prophylatic mastectomy, axillary node dissection, sentinel node and lymphatic mapping, and outpatient mastectomy, as well as coverage of special selected topics featuring breast cancer in pregnancy, inflammatory breast cancer and breast sarcoma. An important section on future research reviews on-going studies for the use of in situ laser ablation, cryosurgery, and translational research to bring the busy practitioner up-to-date on state-of-the art advances. This book is a must-have resource on the full specturm of current and prospective treatment options for this challenging disease.

Published
2012

29. High-Risk Breast Cancer : Therapy

Author

Joseph Ragaz, Irving M. Ariel, Joseph Ragaz, and Irving M. Ariel

Subjects
Breast--Cancer--Treatment, Breast--Cancer--Risk factors, Women--Health risk assessment, Breast Neoplasms--therapy, Risk
Abstract

The many advances in breast cancer research, as well as the large quantity of published material, make it very difficult to gain insight into the global aspects of cancer management. To follow and understand all the new developments is becoming a major challenge. For this reason, the editors decided to bring together a group of top researchers in breast cancer to provide a comprehensive, yet readable conceptual review of the state of the art of breast cancer diagnosis and therapy. The proposal to focus the review on the quantitative assessment of the risk at diagnosis, the determination of which may permit selective therapies for individual patients, was met with enthusiastic approval, resulting in the present volume with contributions by the leading investigators in the field. While the volume relating to diagnosis, published re­ cently, focused on efforts leading to refinement at diagnosis of risk criteria sensitive enough to reliably distinguish the low- and high-risk categories, the second volume, by provid­ ing a review of the main problems and results of therapy given to high-risk patients, can be considered as a continua­ tion of the first book. A refined risk assessment at diagnosis and the application of the most suitable treatments to well­ selected individuals are the most important steps towards avoiding the present worrisome reality of overtreating the low risk and undertreating the high-risk patients. The first few chapters of the present volume offer an insight into the general management of early breast cancer.

Published
2012

30. Aider à vivre après un cancer

Author

MORÈRE Jean-François, ZELEK Laurent, ZERNIK Nicole, MORÈRE Jean-François, ZELEK Laurent, and ZERNIK Nicole

Abstract

La thématique du « survivorship », en plein essor dans les pays anglo-saxons, intègre des dimensions multiples : recherche clinique, épidémiologie, sciences humaines et sociales, éducation sanitaire. En France, les premiers programmes de recherche commencent à voir le jour. Cet ouvrage collectif, rédigé par des spécialistes d'horizons variés, se propose de faire le point sur les différents problèmes rencontrés au cours des années qui suivent le traitement des tumeurs solides localisées de l'adulte. Il s'adresse à tous les praticiens impliqués dans la prise en charge des cancers et de leur suivi. Ils y trouveront traités, entre autres, le problème de la prise en charge multidisciplinaire au long cours des patients en rémission prolongée après traitement d'un cancer, des effets secondaires des traitements, du réaménagement du mode de vie après traitement, des complications tardives des traitements, des possibilités de prévention secondaires et tertiaires, ou bien encore de la question des médecines complémentaires.

Published
2009

31. Brustkrebs : Diagnostik und Therapie Herausgegeben von O. Ortmann und R. Görse Mit einem Geleitwort von U. Veronesi

Author

Zurrida, Stefano, Silva, Orlando E., Zurrida, Stefano, and Silva, Orlando E.

Subjects
Breast--Cancer--Diagnosis, Breast--Cancer--Treatment
Abstract

Die Behandlungsmethoden von Brustkrebs sind vielfältig und entwickeln sich ständig weiter. In diesem Nachschlagewerk finden Sie: alle wesentlichen Leitlinien und Methoden - national und international - zur Behandlung von Brustkrebsneueste Forschungsergebnisse (z.B. Hercepin)umfangreiche Angaben zu Medikamenten, Wirkstoffen, Pharmakologie

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results